Literature DB >> 10092149

The cytostatic effect of 9-cis-retinoic acid, tretinoin, and isotretinoin on three different human bladder cancer cell lines in vitro.

S Laaksovirta1, P Rajala, M Nurmi, T L Tammela, M Laato.   

Abstract

Retinoids have been shown to have activity in both preclinical and clinical bladder cancer studies but their exact role in its treatment and prevention remains obscure. In this study cytostatic activity of a novel 9-cis-retinoic acid (9-cis-RA) was compared with two other retinoids: tretinoin and isotretinoin, in three different bladder cancer cell lines: RT4 (well differentiated), 5637 (moderately differentiated) and T24 (poorly differentiated). The three retinoids were incubated at concentrations of 0.3, 3 and 30 microg/ml with bladder cancer cells in microtitre plates for 3 and 6 days. The cytostatic effect was estimated by using luminometric measuring of ATP activity of viable cells in suspension. Compared with the older retinoids, tretinoin and isotretinoin, the highest concentration of 9-cis-RA had a cytostatic efficacy in all three bladder cancer cell lines tested. A clear dose response relationship was observed in isotretinoin-treated cultures after 6 days and in all 9-cis-RA-treated cultures. Tretinoin was either ineffective or had a stimulating effect on poorly differentiated tumour cells. To conclude, isotretinoin and 9-cis-RA had a cytostatic effect on human bladder cancer cells in vitro. However, the possibility of stimulating cancer growth at small doses, at least with tretinoin, and toxicity at high doses must be considered when planning clinical trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092149     DOI: 10.1007/s002400050084

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  4 in total

1.  Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.

Authors:  Sarah Schott; Markus Wallwiener; Beate Kootz; Harald Seeger; Tanja Fehm; Hans Neubauer
Journal:  Invest New Drugs       Date:  2011-05-21       Impact factor: 3.850

2.  ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.

Authors:  Sarah Schott; Markus Wallwiener; Beate Kootz; Harald Seeger; Tanja Fehm; Hans Neubauer
Journal:  Invest New Drugs       Date:  2009-12-09       Impact factor: 3.850

3.  Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.

Authors:  Junfei Zhao; Feixiong Cheng; Yuanyuan Wang; Carlos L Arteaga; Zhongming Zhao
Journal:  Mol Cell Proteomics       Date:  2015-12-09       Impact factor: 5.911

Review 4.  Vitamin A and Retinoids in Bladder Cancer Chemoprevention and Treatment: A Narrative Review of Current Evidence, Challenges and Future Prospects.

Authors:  Larisa Tratnjek; Jera Jeruc; Rok Romih; Daša Zupančič
Journal:  Int J Mol Sci       Date:  2021-03-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.